Middle class: Lonza on the flexibility of midscale biomanufacturing
With construction of a 6,000 L scale hybrid plant underway, CDMO Lonza says there is high demand among its customers for midscale biomanufacturing. In this industry, companies and commentators like talking about extremes: either small-scale single-use or large-scale stainless steel. But speaking ...
MilliporeSigma intends to add an additional 38,500 square feet of manufacturing space at its site in New Hampshire to support demand for filtrati ...
Amgen says it hopes to rapidly develop new medicines from a collaboration with Intermountain Health as its EVP of R&D discusses changing time ...
Fujifilm Diosynth Biotechnologies says it can overcome the burden of large buffer volumes associated with continuous purification as part of a ne ...
With the FDA approving Amgen And Allergan's version of Roche’s Herceptin (trastuzumab) America’s biosimilar tally has reached 20… But only ...
Recent Tweets
-
RT @Dan5tanton: Middle class: With construction of a 6,000 L scale hybrid plant underway, CDMO Lonza told @BioProInsider at… https://t.co/HTKy5cZ3NI
11 hours ago
-
RT @Dan5tanton: America has 20 approved biosimilars but you’ll never believe how many have launched! https://t.co/ohlbrlwPQa https://t.co/R6VoZzfQZh
3 days ago
-
RT @Dan5tanton: bluebird bio will use #CDMO Hitachi Chemical subsidiary apceth Biopharma to commercially manufacture its recently E… https://t.co/1INLBy8pBT
4 days ago
-
RT @Dan5tanton: The Jefferson Institute for Bioprocessing (JIB) has opened its doors in Pennsylvania. @BioProInsider visited to fin… https://t.co/xaJ3hZDRm2
5 days ago
